The role of Vif oligomerization and RNA chaperone activity in HIV-1 replication

Virus Research

Volumn 169, Issue 2, 2012, Pages 361-376

  Batisse, Julien ^a   Guerrero, Santiago ^a   Bernacchi, Serena ^a   Sleiman, Dona ^b   Gabus, Caroline ^c   Darlix, Jean Luc ^a,c   Marquet, Roland ^a   Tisné, Carine ^b   Paillart, Jean Christophe ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c UNIVERSITÉ LYON 1   (France)

Author keywords

HIV 1; Protein oligomerization; RNA chaperone; Vif

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; CHAPERONE; ELONGIN B; ELONGIN C; GAG PROTEIN; GENOMIC RNA; HAMMERHEAD RIBOZYME; RNA; UBIQUITIN PROTEIN LIGASE E3; VIF PROTEIN; VIRUS DNA;

5' UNTRANSLATED REGION; ANTIVIRAL ACTIVITY; ARTICLE; CARBOXY TERMINAL SEQUENCE; CRYSTAL STRUCTURE; CRYSTALLIZATION; DIMERIZATION; DNA SYNTHESIS; DNA TRANSFER; HUMAN IMMUNODEFICIENCY VIRUS 1; MUTAGENESIS; NONHUMAN; OLIGOMERIZATION; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROCESSING; PROTEIN SECONDARY STRUCTURE; REVERSE TRANSCRIPTION; RNA BINDING; RNA CLEAVAGE; RNA CONFORMATION; RNA FOLDING; RNA TRANSLATION; VIRION; VIRUS ASSEMBLY; VIRUS INFECTIVITY; VIRUS NEUTRALIZATION; VIRUS PARTICLE; VIRUS REPLICATION; ZINC FINGER MOTIF;

HIV-1; MOLECULAR CHAPERONES; PROTEIN MULTIMERIZATION; RNA, TRANSFER, LYS; RNA, VIRAL; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRUS ASSEMBLY;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 84868619872     PISSN: 01681702     EISSN: 18727492     Source Type: Journal    
DOI: 10.1016/j.virusres.2012.06.018     Document Type: Article

References (188)

1. Akari H., Yoshida A., Fukumori T., Adachi A. Host cell-dependent replication of HIV-1 mutants with deletions in gp41 cytoplasmic tail region is independent of the function of Vif. Microbes and Infection 2000, 2(9):1019-1023.
2. Akari H., Fujita M., Kao S., Khan M.A., Shehu-Xhilaga M., Adachi A., Strebel K. High level expression of human immunodeficiency virus type-1 Vif inhibits viral infectivity by modulating proteolytic processing of the Gag precursor at the p2/nucleocapsid processing site. Journal of Biological Chemistry 2004, 279(13):12355-12362.
3. Albin J.S., Harris R.S. Interactions of host APOBEC3 restriction factors with HIV-1 in vivo: implications for therapeutics. Expert Reviews in Molecular Medicine 2010, 12:e4.
4. Anderson J.L., Hope T.J. APOBEC3G restricts early HIV-1 replication in the cytoplasm of target cells. Virology 2008, 375(1):1-12.
5. Apolloni A., Meredith L.W., Suhrbier A., Kiernan R., Harrich D. The HIV-1 Tat protein stimulates reverse transcription in vitro. Current HIV Research 2007, 5(5):473-483.
6. Balaji S., Kalpana R., Shapshak P. Paradigm development: comparative and predictive 3D modeling of HIV-1 virion infectivity factor (Vif). Bioinformation 2006, 1(8):290-309.
7. Bampi C., Bibillo A., Wendeler M., Divita G., Gorelick R.J., Le Grice S.F., Darlix J.L. Nucleotide excision repair and template-independent addition by HIV-1 reverse transcriptase in the presence of nucleocapsid protein. Journal of Biological Chemistry 2006, 281(17):11736-11743.
8. Baraz L., Hutoran M., Blumenzweig I., Katzenellenbogen M., Friedler A., Gilon C., Steinitz M., Kotler M. Human immunodeficiency virus type 1 Vif binds the viral protease by interaction with its N-terminal region. Journal of General Virology 2002, 83(Pt 9):2225-2230.
9. Bardy M., Gay B., Pebernard S., Chazal N., Courcoul M., Vigne R., Decroly E., Boulanger P. Interaction of human immunodeficiency virus type 1 Vif with Gag and Gag-Pol precursors: co-encapsidation and interference with viral protease-mediated Gag processing. Journal of General Virology 2001, 82(Pt 11):2719-2733.
10. Barraud P., Gaudin C., Dardel F., Tisné C. New insights into the formation of HIV-1 reverse transcription initiation complex. Biochimie 2007, 89(10):1204-1210.
11. Barraud P., Paillart J.C., Marquet R., Tisné C. Advances in the structural understanding of Vif proteins. Current HIV Research 2008, 6(2):91-99.
12. Basu V.P., Song M., Gao L., Rigby S.T., Hanson M.N., Bambara R.A. Strand transfer events during HIV-1 reverse transcription. Virus Research 2008, 134(1-2):19-38.
13. Beltz H., Azoulay J., Bernacchi S., Clamme J.P., Ficheux D., Roques B., Darlix J.L., Mely Y. Impact of the terminal bulges of HIV-1 cTAR DNA on its stability and the destabilizing activity of the nucleocapsid protein NCp7. Journal of Molecular Biology 2003, 328(1):95-108.
14. Berger G., Durand S., Fargier G., Nguyen X.N., Cordeil S., Bouaziz S., Muriaux D., Darlix J.L., Cimarelli A. APOBEC3A is a specific inhibitor of the early phases of HIV-1 infection in myeloid cells. PLoS Pathogens 2011, 7(9):e1002221.
15. Bergeron J.R., Huthoff H., Veselkov D.A., Beavil R.L., Simpson P.J., Matthews S.J., Malim M.H., Sanderson M.R. The SOCS-box of HIV-1 Vif interacts with Elongin BC by induced-folding to recruit its Cul5-containing ubiquitin ligase complex. PLoS Pathogens 2010, 6(6):e1000925.
16. Bernacchi S., Henriet S., Dumas P., Paillart J.C., Marquet R. RNA and DNA binding properties of HIV-1 Vif protein: a fluorescence study. Journal of Biological Chemistry 2007, 282(36):26361-26368.
17. Bernacchi S., Mercenne G., Tournaire C., Marquet R., Paillart J.C. Importance of the proline-rich multimerization domain on the oligomerization and nucleic acid binding properties of HIV-1 Vif. Nucleic Acids Research 2011, 39(6):2404-2415.
18. Binka M., Ooms M., Steward M., Simon V. The activity spectrum of Vif from multiple HIV-1 subtypes against APOBEC3G, APOBEC3F, and APOBEC3H. Journal of Virology 2012, 86(1):49-59.
19. Bishop K.N., Holmes R.K., Malim M.H. Antiviral potency of APOBEC proteins does not correlate with cytidine deamination. Journal of Virology 2006, 80(17):8450-8458.
20. Bishop K.N., Verma M., Kim E.Y., Wolinsky S.M., Malim M.H. APOBEC3G inhibits elongation of HIV-1 reverse transcripts. PLoS Pathogens 2008, 4(12):e1000231.
21. Borman A.M., Quillent C., Charneau P., Dauguet C., Clavel F. Human immunodeficiency virus type 1 Vif-mutant particles from restrictive cells: role of Vif in correct particle assembly and infectivity. Journal of Virology 1995, 69(4):2058-2067.
22. Boudier C., Storchak R., Sharma K.K., Didier P., Follenius-Wund A., Muller S., Darlix J.L., Mely Y. The mechanism of HIV-1 Tat-directed nucleic acid annealing supports its role in reverse transcription. Journal of Molecular Biology 2010, 400(3):487-501.
23. Bouyac M., Courcoul M., Bertoia G., Baudat Y., Gabuzda D., Blanc D., Chazal N., Boulanger P., Sire J., Vigne R., Spire B. Human immunodeficiency virus type 1 Vif protein binds to the Pr55Gag precursor. Journal of Virology 1997, 71(12):9358-9365.
24. Brule F., Marquet R., Rong L., Wainberg M.A., Roques B.P., Le Grice S.F., Ehresmann B., Ehresmann C. Structural and functional properties of the HIV-1 RNA-tRNA(Lys)3 primer complex annealed by the nucleocapsid protein: comparison with the heat-annealed complex. RNA 2002, 8(1):8-15.
25. Burnett A., Spearman P. APOBEC3G multimers are recruited to the plasma membrane for packaging into human immunodeficiency virus type 1 virus-like particles in an RNA-dependent process requiring the NC basic linker. Journal of Virology 2007, 81(10):5000-5013.
26. Carr J.M., Davis A.J., Coolen C., Cheney K., Burrell C.J., Li P. Vif-deficient HIV reverse transcription complexes (RTCs) are subject to structural changes and mutation of RTC-associated reverse transcription products. Virology 2006, 351(1):80-91.
27. Carr J.M., Coolen C., Davis A.J., Burrell C.J., Li P. Human immunodeficiency virus 1 (HIV-1) virion infectivity factor (Vif) is part of reverse transcription complexes and acts as an accessory factor for reverse transcription. Virology 2008, 372(1):147-156.
28. Chen J., Nikolaitchik O., Singh J., Wright A., Bencsics C.E., Coffin J.M., Ni N., Lockett S., Pathak V.K., Hu W.S. High efficiency of HIV-1 genomic RNA packaging and heterozygote formation revealed by single virion analysis. Proceedings of the National Academy of Sciences of the United States of America 2009, 106(32):13535-13540.
29. Chertova E., Chertov O., Coren L.V., Roser J.D., Trubey C.M., Bess J.W., Sowder R.C., Barsov E., Hood B.L., Fisher R.J., Nagashima K., Conrads T.P., Veenstra T.D., Lifson J.D., Ott D.E. Proteomic and biochemical analysis of purified human immunodeficiency virus type 1 produced from infected monocyte-derived macrophages. Journal of Virology 2006, 80(18):9039-9052.
30. Cimarelli A., Darlix J.L. Assembling the human immunodeficiency virus type 1. Cellular and Molecular Life Sciences 2002, 59(7):1166-1184.
31. Clodi E., Semrad K., Schroeder R. Assaying RNA chaperone activity in vivo using a novel RNA folding trap. EMBO Journal 1999, 18(13):3776-3782.
32. Conticello S.G., Harris R.S., Neuberger M.S. The Vif protein of HIV triggers degradation of the human antiretroviral DNA deaminase APOBEC3G. Current Biology 2003, 13(22):2009-2013.
33. Courcoul M., Patience C., Rey F., Blanc D., Harmache A., Sire J., Vigne R., Spire B. Peripheral blood mononuclear cells produce normal amounts of defective Vif-human immunodeficiency virus type 1 particles which are restricted for the preretrotranscription steps. Journal of Virology 1995, 69(4):2068-2074.
34. Cristofari G., Darlix J.L. The ubiquitous nature of RNA chaperone proteins. Progress in Nucleic Acid Research and Molecular Biology 2002, 72:223-268.
35. Dafonseca S., Coric P., Gay B., Hong S.S., Bouaziz S., Boulanger P. The inhibition of assembly of HIV-1 virus-like particles by 3-O-(3',3'-dimethylsuccinyl) betulinic acid (DSB) is counteracted by Vif and requires its zinc-binding domain. Virology Journal 2008, 5:162.
36. Darlix J.L., Godet J., Ivanyi-Nagy R., Fosse P., Mauffret O., Mely Y. Flexible nature and specific functions of the HIV-1 nucleocapsid protein. Journal of Molecular Biology 2011, 410(4):565-581.
37. Dettenhofer M., Cen S., Carlson B.A., Kleiman L., Yu X.F. Association of human immunodeficiency virus type 1 Vif with RNA and its role in reverse transcription. Journal of Virology 2000, 74(19):8938-8945.
38. Didierlaurent L., Houzet L., Morichaud Z., Darlix J.L., Mougel M. The conserved N-terminal basic residues and zinc-finger motifs of HIV-1 nucleocapsid restrict the viral cDNA synthesis during virus formation and maturation. Nucleic Acids Research 2008, 36(14):4745-4753.
39. Donahue J.P., Vetter M.L., Mukhtar N.A., D'Aquila R.T. The HIV-1 Vif PPLP motif is necessary for human APOBEC3G binding and degradation. Virology 2008, 377(1):49-53.
40. Douaisi M., Dussart S., Courcoul M., Bessou G., Lerner E.C., Decroly E., Vigne R. The tyrosine kinases Fyn and Hck favor the recruitment of tyrosine-phosphorylated APOBEC3G into Vif-defective HIV-1 particles. Biochemical and Biophysical Research Communications 2005, 329(3):917-924.
41. Driscoll M.D., Hughes S.H. Human immunodeficiency virus type 1 nucleocapsid protein can prevent self-priming of minus-strand strong stop DNA by promoting the annealing of short oligonucleotides to hairpin sequences. Journal of Virology 2000, 74(19):8785-8792.
42. Fan L., Peden K. Cell-free transmission of Vif mutants of HIV-1. Virology 1992, 190(1):19-29.
43. Fisher A.G., Ensoli B., Ivanoff L., Chamberlain M., Petteway S., Ratner L., Gallo R.C., Wong-Staal F. The sor gene of HIV-1 is required for efficient virus transmission in vitro. Science 1987, 237(4817):888-893.
44. Fouchier R.A., Simon J.H., Jaffe A.B., Malim M.H. Human immunodeficiency virus type 1 Vif does not influence expression or virion incorporation of gag-, pol-, and env-encoded proteins. Journal of Virology 1996, 70(12):8263-8269.
45. Fujita M., Sakurai A., Yoshida A., Miyaura M., Koyama A.H., Sakai K., Adachi A. Amino acid residues 88 and 89 in the central hydrophilic region of human immunodeficiency virus type 1 Vif are critical for viral infectivity by enhancing the steady-state expression of Vif. Journal of Virology 2003, 77(2):1626-1632.
46. + T lymphocytes. Journal of Virology 1992, 66(11):6489-6495.
47. Goncalves J., Shi B., Yang X., Gabuzda D. Biological activity of human immunodeficiency virus type 1 Vif requires membrane targeting by C-terminal basic domains. Journal of Virology 1995, 69(11):7196-7204.
48. Grigorov B., Bocquin A., Gabus C., Avilov S., Mely Y., Agopian A., Divita G., Gottikh M., Witvrouw M., Darlix J.L. Identification of a methylated oligoribonucleotide as a potent inhibitor of HIV-1 reverse transcription complex. Nucleic Acids Research 2011, 39(13):5586-5596.
49. Guo J., Henderson L.E., Bess J., Kane B., Levin J.G. Human immunodeficiency virus type 1 nucleocapsid protein promotes efficient strand transfer and specific viral DNA synthesis by inhibiting TAR-dependent self-priming from minus-strand strong-stop DNA. Journal of Virology 1997, 71(7):5178-5188.
50. Guo F., Cen S., Niu M., Yang Y., Gorelick R.J., Kleiman L. The interaction of APOBEC3G with human immunodeficiency virus type 1 nucleocapsid inhibits tRNA3Lys annealing to viral RNA. Journal of Virology 2007, 81(20):11322-11331.
51. Hargittai M.R., Gorelick R.J., Rouzina I., Musier-Forsyth K. Mechanistic insights into the kinetics of HIV-1 nucleocapsid protein-facilitated tRNA annealing to the primer binding site. Journal of Molecular Biology 2004, 337(4):951-968.
52. Harris R.S., Petersen-Mahrt S.K., Neuberger M.S. RNA editing enzyme APOBEC1 and some of its homologs can act as DNA mutators. Molecular Cell 2002, 10(5):1247-1253.
53. Harris R.S., Bishop K.N., Sheehy A.M., Craig H.M., Petersen-Mahrt S.K., Watt I.N., Neuberger M.S., Malim M.H. DNA deamination mediates innate immunity to retroviral infection. Cell 2003, 113(6):803-809.
54. Hassaine G., Courcoul M., Bessou G., Barthalay Y., Picard C., Olive D., Collette Y., Vigne R., Decroly E. The tyrosine kinase Hck is an inhibitor of HIV-1 replication counteracted by the viral Vif protein. Journal of Biological Chemistry 2001, 276(20):16885-16893.
55. He B., Wang K., Liu Y., Xue B., Uversky V.N., Dunker A.K. Predicting intrinsic disorder in proteins: an overview. Cell Research 2009, 19(8):929-949.
56. Henriet S., Richer D., Bernacchi S., Decroly E., Vigne R., Ehresmann B., Ehresmann C., Paillart J.C., Marquet R. Cooperative and specific binding of Vif to the 5' region of HIV-1 genomic RNA. Journal of Molecular Biology 2005, 354(1):55-72.
57. Henriet S., Sinck L., Bec G., Gorelick R.J., Marquet R., Paillart J.C. Vif is a RNA chaperone that could temporally regulate RNA dimerization and the early steps of HIV-1 reverse transcription. Nucleic Acids Research 2007, 35(15):5141-5153.
58. Henriet S., Mercenne G., Bernacchi S., Paillart J.C., Marquet R. Tumultuous relationship between the human immunodeficiency virus type 1 viral infectivity factor (Vif) and the human APOBEC-3G and APOBEC-3F restriction factors. Microbiology and Molecular Biology Reviews 2009, 73(2):211-232.
59. Herschlag D. RNA chaperones and the RNA folding problem. Journal of Biological Chemistry 1995, 270:20871-20874.
60. Hoglund S., Ohagen A., Lawrence K., Gabuzda D. Role of Vif during packing of the core of HIV-1. Virology 1994, 201(2):349-355.
61. Holmes R.K., Koning F.A., Bishop K.N., Malim M.H. APOBEC3F can inhibit the accumulation of HIV-1 reverse transcription products in the absence of hypermutation. Comparisons with APOBEC3G. Journal of Biological Chemistry 2007, 282(4):2587-2595.
62. Housset V., de Rocquigny H., Roques B.P., Darlix J.L. Basic amino acids flanking the zinc finger of Moloney murine leukemia virus nucleocapsid protein NCp10 are critical for virus infectivity. Journal of Virology 1993, 67(5):2537-2545.
63. Houzet L., Morichaud Z., Didierlaurent L., Muriaux D., Darlix J.L., Mougel M. Nucleocapsid mutations turn HIV-1 into a DNA-containing virus. Nucleic Acids Research 2008, 36(7):2311-2319.
64. Hultquist J.F., Binka M., Larue R.S., Simon V., Harris R.S. Vif proteins of human and simian immunodeficiency viruses require cellular CBFbeta to degrade APOBEC3 restriction factors. Journal of Virology 2011.
65. Hultquist J.F., Lengyel J.A., Refsland E.W., LaRue R.S., Lackey L., Brown W.L., Harris R.S. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity to restrict Vif-deficient HIV-1. Journal of Virology 2011, 85(21):11220-11234.
66. Hultquist J.F., Binka M., LaRue R.S., Simon V., Harris R.S. Vif proteins of human and simian immunodeficiency viruses require cellular CBFbeta to degrade APOBEC3 restriction factors. Journal of Virology 2012, 86(5):2874-2877.
67. Isel C., Ehresmann C., Keith G., Ehresmann B., Marquet R. Initiation of reverse transcription of HIV-1: secondary structure of the HIV-1 RNA/tRNA(3Lys) (template/primer). Journal of Molecular Biology 1995, 247(2):236-250.
68. Isel C., Ehresmann C., Marquet R. Initiation of HIV reverse transcription. Viruses 2010, 2(1):213-243.
69. Ivanyi-Nagy R., Lavergne J.P., Gabus C., Ficheux D., Darlix J.L. RNA chaperoning and intrinsic disorder in the core proteins of Flaviviridae. Nucleic Acids Research 2008, 36(3):712-725.
70. Iwai K., Yamanaka K., Kamura T., Minato N., Conaway R.C., Conaway J.W., Klausner R.D., Pause A. Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex. Proceedings of the National Academy of Sciences of United States of America 1999, 96(22):12436-12441.
71. Iwatani Y., Chan D.S., Wang F., Maynard K.S., Sugiura W., Gronenborn A.M., Rouzina I., Williams M.C., Musier-Forsyth K., Levin J.G. Deaminase-independent inhibition of HIV-1 reverse transcription by APOBEC3G. Nucleic Acids Research 2007, 35:7096-7108.
72. Izumi T., Takaori-Kondo A., Shirakawa K., Higashitsuji H., Itoh K., Io K., Matsui M., Iwai K., Kondoh H., Sato T., Tomonaga M., Ikeda S., Akari H., Koyanagi Y., Fujita J., Uchiyama T. MDM2 is a novel E3 ligase for HIV-1 Vif. Retrovirology 2009, 6:1.
73. Jager S., Kim D.Y., Hultquist J.F., Shindo K., Larue R.S., Kwon E., Li M., Anderson B.D., Yen L., Stanley D., Mahon C., Kane J., Franks-Skiba K., Cimermancic P., Burlingame A., Sali A., Craik C.S., Harris R.S., Gross J.D., Krogan N.J. Vif hijacks CBF-beta to degrade APOBEC3G and promote HIV-1 infection. Nature 2011.
74. Jager S., Cimermancic P., Gulbahce N., Johnson J.R., McGovern K.E., Clarke S.C., Shales M., Mercenne G., Pache L., Li K., Hernandez H., Jang G.M., Roth S.L., Akiva E., Marlett J., Stephens M., D'Orso I., Fernandes J., Fahey M., Mahon C., O'Donoghue A.J., Todorovic A., Morris J.H., Maltby D.A., Alber T., Cagney G., Bushman F.D., Young J.A., Chanda S.K., Sundquist W.I., Kortemme T., Hernandez R.D., Craik C.S., Burlingame A., Sali A., Frankel A.D., Krogan N.J. Global landscape of HIV-human protein complexes. Nature 2012, 481(7381):365-370.
75. Jarmuz A., Chester A., Bayliss J., Gisbourne J., Dunham I., Scott J., Navaratnam N. An anthropoid-specific locus of orphan C to U RNA-editing enzymes on chromosome 22. Genomics 2002, 79(3):285-296.
76. Ji X., Klarmann G.J., Preston B.D. Effect of human immunodeficiency virus type 1 (HIV-1) nucleocapsid protein on HIV-1 reverse transcriptase activity in vitro. Biochemistry 1996, 35:132-143.
77. Kameoka M., Rong L., Gotte M., Liang C., Russell R.S., Wainberg M.A. Role for human immunodeficiency virus type 1 Tat protein in suppression of viral reverse transcriptase activity during late stages of viral replication. Journal of Virology 2001, 75(6):2675-2683.
78. Kameoka M., Morgan M., Binette M., Russell R.S., Rong L., Guo X., Mouland A., Kleiman L., Liang C., Wainberg M.A. The Tat protein of human immunodeficiency virus type 1 (HIV-1) can promote placement of tRNA primer onto viral RNA and suppress later DNA polymerization in HIV-1 reverse transcription. Journal of Virology 2002, 76(8):3637-3645.
79. Kao S., Khan M.A., Miyagi E., Plishka R., Buckler-White A., Strebel K. The human immunodeficiency virus type 1 Vif protein reduces intracellular expression and inhibits packaging of APOBEC3G (CEM15), a cellular inhibitor of virus infectivity. Journal of Virology 2003, 77(21):11398-11407.
80. Kataropoulou A., Bovolenta C., Belfiore A., Trabatti S., Garbelli A., Porcellini S., Lupo R., Maga G. Mutational analysis of the HIV-1 auxiliary protein Vif identifies independent domains important for the physical and functional interaction with HIV-1 reverse transcriptase. Nucleic Acids Research 2009, 37(11):3660-3669.
81. Khan M.A., Aberham C., Kao S., Akari H., Gorelick R., Bour S., Strebel K. Human immunodeficiency virus type 1 Vif protein is packaged into the nucleoprotein complex through an interaction with viral genomic RNA. Journal of Virology 2001, 75(16):7252-7265.
82. Khan M.A., Akari H., Kao S., Aberham C., Davis D., Buckler-White A., Strebel K. Intravirion processing of the human immunodeficiency virus type 1 Vif protein by the viral protease may be correlated with Vif function. Journal of Virology 2002, 76(18):9112-9123.
83. Khan M.A., Kao S., Miyagi E., Takeuchi H., Goila-Gaur R., Opi S., Gipson C.L., Parslow T.G., Ly H., Strebel K. Viral RNA is required for the association of APOBEC3G with human immunodeficiency virus type 1 nucleoprotein complexes. Journal of Virology 2005, 79(9):5870-5874.
84. Kitamura S., Ode H., Iwatani Y. Structural features of antiviral APOBEC3 proteins are linked to their functional activities. Frontiers in Microbiology 2011, 2:258.
85. Kotler M., Simm M., Zhao Y.S., Sova P., Chao W., Ohnona S.F., Roller R., Krachmarov C., Potash M.J., Volsky D.J. Human immunodeficiency virus type 1 (HIV-1) protein Vif inhibits the activity of HIV-1 protease in bacteria and in vitro. Journal of Virology 1997, 71(8):5774-5781.
86. Kovacs D., Rakacs M., Agoston B., Lenkey K., Semrad K., Schroeder R., Tompa P. Janus chaperones: assistance of both RNA- and protein-folding by ribosomal proteins. FEBS Letters 2009, 583(1):88-92.
87. Kuciak M., Gabus C., Ivanyi-Nagy R., Semrad K., Storchak R., Chaloin O., Muller S., Mely Y., Darlix J.L. The HIV-1 transcriptional activator Tat has potent nucleic acid chaperoning activities in vitro. Nucleic Acids Research 2008, 36(10):3389-3400.
88. Lecossier D., Bouchonnet F., Clavel F., Hance A.J. Hypermutation of HIV-1 DNA in the absence of the Vif protein. Science 2003, 300(5622):1112.
89. Lee Y.M., Liu B., Yu X.F. Formation of virus assembly intermediate complexes in the cytoplasm by wild-type and assembly-defective mutant human immunodeficiency virus type 1 and their association with membranes. Journal of Virology 1999, 73(7):5654-5662.
90. 3,lys in vitro: studies of viral RNA molecules mutated in regions that flank the primer binding site. Journal of Virology 1996, 70:4996-5004.
91. Li X.Y., Guo F., Zhang L., Kleiman L., Cen S. APOBEC3G inhibits DNA strand transfer during HIV-1 reverse transcription. Journal of Biological Chemistry 2007, 282(44):32065-32074.
92. Liddament M.T., Brown W.L., Schumacher A.J., Harris R.S. APOBEC3F properties and hypermutation preferences indicate activity against HIV-1 in vivo. Current Biology 2004, 14(15):1385-1391.
93. Liu B., Sarkis P.T., Luo K., Yu Y., Yu X.F. Regulation of Apobec3F and human immunodeficiency virus type 1 Vif by Vif-Cul5-ElonB/C E3 ubiquitin ligase. Journal of Virology 2005, 79(15):9579-9587.
94. Lu K., Heng X., Summers M.F. Structural determinants and mechanism of HIV-1 genome packaging. Journal of Molecular Biology 2011, 410(4):609-633.
95. Luo K., Liu B., Xiao Z., Yu Y., Yu X., Gorelick R., Yu X.F. Amino-terminal region of the human immunodeficiency virus type 1 nucleocapsid is required for human APOBEC3G packaging. Journal of Virology 2004, 78(21):11841-11852.
96. Luo K., Xiao Z., Ehrlich E., Yu Y., Liu B., Zheng S., Yu X.F. Primate lentiviral virion infectivity factors are substrate receptors that assemble with cullin 5-E3 ligase through a HCCH motif to suppress APOBEC3G. Proceedings of the National Academy of Sciences of United States of America 2005, 102(32):11444-11449.
97. Luo K., Wang T., Liu B., Tian C., Xiao Z., Kappes J., Yu X.F. Cytidine deaminases APOBEC3G and APOBEC3F interact with human immunodeficiency virus type 1 integrase and inhibit proviral DNA formation. Journal of Virology 2007, 81(13):7238-7248.
98. Lv W., Liu Z., Jin H., Yu X., Zhang L., Zhang L. Three-dimensional structure of HIV-1 Vif constructed by comparative modeling and the function characterization analyzed by molecular dynamics simulation. Organic & Biomolecular Chemistry 2007, 5(4):617-626.
99. Madani N., Kabat D. An endogenous inhibitor of human immunodeficiency virus in human lymphocytes is overcome by the viral Vif protein. Journal of Virology 1998, 72(12):10251-10255.
100. Malim M.H., Emerman M. HIV-1 accessory proteins-ensuring viral survival in a hostile environment. Cell Host & Microbe 2008, 3(6):388-398.
101. Mandal D., Exline C.M., Feng Z., Stoltzfus C.M. Regulation of Vif mRNA splicing by human immunodeficiency virus type 1 requires 5' splice site D2 and an exonic splicing enhancer to counteract cellular restriction factor APOBEC3G. Journal of Virology 2009, 83(12):6067-6078.
102. Mangeat B., Turelli P., Caron G., Friedli M., Perrin L., Trono D. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 2003, 424(6944):99-103.
103. Marcsisin S.R., Engen J.R. Molecular insight into the conformational dynamics of the Elongin BC complex and its interaction with HIV-1 Vif. Journal of Molecular Biology 2010, 402(5):892-904.
104. Marcsisin S.R., Narute P.S., Emert-Sedlak L.A., Kloczewiak M., Smithgall T.E., Engen J.R. On the solution conformation and dynamics of the HIV-1 viral infectivity factor. Journal of Molecular Biology 2011, 410(5):1008-1022.
105. Mariani R., Chen D., Schrofelbauer B., Navarro F., Konig R., Bollman B., Munk C., Nymark-McMahon H., Landau N.R. Species-specific exclusion of APOBEC3G from HIV-1 virions by Vif. Cell 2003, 114(1):21-31.
106. Marin M., Rose K.M., Kozak S.L., Kabat D. HIV-1 Vif protein binds the editing enzyme APOBEC3G and induces its degradation. Nature Medicine 2003, 9(11):1398-1403.
107. Mbisa J.L., Barr R., Thomas J.A., Vandegraaff N., Dorweiler I.J., Svarovskaia E.S., Brown W.L., Mansky L.M., Gorelick R.J., Harris R.S., Engelman A., Pathak V.K. Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integration. Journal of Virology 2007, 81(13):7099-7110.
108. McGuffin L.J., Bryson K., Jones D.T. The PSIPRED protein structure prediction server. Bioinformatics 2000, 16(4):404-405.
109. Mehle A., Goncalves J., Santa-Marta M., McPike M., Gabuzda D. Phosphorylation of a novel SOCS-box regulates assembly of the HIV-1 Vif-Cul5 complex that promotes APOBEC3G degradation. Genes and Development 2004, 18(23):2861-2866.
110. Mehle A., Strack B., Ancuta P., Zhang C., McPike M., Gabuzda D. Vif overcomes the innate antiviral activity of APOBEC3G by promoting its degradation in the ubiquitin-proteasome pathway. Journal of Biological Chemistry 2004, 279(9):7792-7798.
111. Mehle A., Thomas E.R., Rajendran K.S., Gabuzda D. A zinc-binding region in Vif binds Cul5 and determines cullin selection. Journal of Biological Chemistry 2006, 281(25):17259-17265.
112. Mehle A., Wilson H., Zhang C., Brazier A.J., McPike M., Pery E., Gabuzda D. Identification of an APOBEC3G binding site in human immunodeficiency virus type 1 Vif and inhibitors of Vif-APOBEC3G binding. Journal of Virology 2007, 81(23):13235-13241.
113. Mercenne G., Bernacchi S., Richer D., Bec G., Henriet S., Paillart J.C., Marquet R. HIV-1 Vif binds to APOBEC3G mRNA and inhibits its translation. Nucleic Acids Research 2010, 38(2):633-646.
114. Miller J.H., Presnyak V., Smith H.C. The dimerization domain of HIV-1 viral infectivity factor Vif is required to block APOBEC3G incorporation with virions. Retrovirology 2007, 4:81.
115. Miyagi E., Opi S., Takeuchi H., Khan M., Goila-Gaur R., Kao S., Strebel K. Enzymatically active APOBEC3G is required for efficient inhibition of HIV-1. Journal of Virology 2007, 81:13346-13353.
116. Mougel M., Houzet L., Darlix J.L. When is it time for reverse transcription to start and go?. Retrovirology 2009, 6:24.
117. Muriaux D., Darlix J.L. Properties and functions of the nucleocapsid protein in virus assembly. RNA Biology 2010, 7(6):744-753.
118. Muriaux D., De R.H., Roques B.P., Paoletti J. NCp7 activates HIV-1Lai RNA dimerization by converting a transient loop-loop complex into a stable dimer. Journal of Biological Chemistry 1996, 271(52):33686-33692.
119. Newman E.N., Holmes R.K., Craig H.M., Klein K.C., Lingappa J.R., Malim M.H., Sheehy A.M. Antiviral function of APOBEC3G can be dissociated from cytidine deaminase activity. Current Biology 2005, 15(2):166-170.
120. Ohagen A., Gabuzda D. Role of Vif in stability of the human immunodeficiency virus type 1 core. Journal of Virology 2000, 74(23):11055-11066.
121. Opi S., Kao S., Goila-Gaur R., Khan M.A., Miyagi E., Takeuchi H., Strebel K. Human immunodeficiency virus type 1 Vif inhibits packaging and antiviral activity of a degradation-resistant APOBEC3G variant. Journal of Virology 2007, 81(15):8236-8246.
122. Paillart J.-C., Marquet R., Skripkin E., Ehresmann C., Ehresmann B. Dimerization of retroviral genomic RNAs: structural and functional implications. Biochimie 1996, 78(7):639-653.
123. Paillart J.-C., Shehu-Xhilaga M., Marquet R., Mak J. Dimerization of retroviral RNA genomes: an inseparable pair. Nature Reviews Microbiology 2004, 2:461-472.
124. Paul I., Cui J., Maynard E.L. Zinc binding to the HCCH motif of HIV-1 virion infectivity factor induces a conformational change that mediates protein-protein interactions. Proceedings of the National Academy of Sciences of United States of America 2006, 103(49):18475-18480.
125. Pery E., Rajendran K.S., Brazier A.J., Gabuzda D. Regulation of APOBEC3 proteins by a novel YXXL motif in human immunodeficiency virus type 1 Vif and simian immunodeficiency virus SIVagm Vif. Journal of Virology 2009, 83(5):2374-2381.
126. Prats A.C., Sarih L., Gabus C., Litvak S., Keith G., Darlix J.L. Small finger protein of avian and murine retroviruses has nucleic acid annealing activity and positions the replication primer tRNA onto genomic RNA. EMBO Journal 1988, 7(6):1777-1783.
127. Rajkowitsch L., Chen D., Stampfl S., Semrad K., Waldsich C., Mayer O., Jantsch M.F., Konrat R., Blasi U., Schroeder R. RNA chaperones, RNA annealers and RNA helicases. RNA Biology 2007, 4(3):118-130.
128. Reddy T.R., Kraus G., Yamada O., Looney D.J., Suhasini M., Wong-Staal F. Comparative analyses of human immunodeficiency virus type 1 (HIV-1) and HIV-2 Vif mutants. Journal of Virology 1995, 69(6):3549-3553.
129. Rein A. Nucleic acid chaperone activity of retroviral Gag proteins. RNA Biology 2010, 7(6):700-705.
130. Reingewertz T.H., Benyamini H., Lebendiker M., Shalev D.E., Friedler A. The C-terminal domain of the HIV-1 Vif protein is natively unfolded in its unbound state. Protein Engineering, Design Selection 2009, 22(5):281-287.
131. Reingewertz T.H., Shalev D.E., Friedler A. Structural disorder in the HIV-1 Vif protein and interaction-dependent gain of structure. Protein and Peptide Letters 2010, 17(8):988-998.
132. Russell R.A., Pathak V.K. Identification of two distinct human immunodeficiency virus type 1 Vif determinants critical for interactions with human APOBEC3G and APOBEC3F. Journal of Virology 2007, 81(15):8201-8210.
133. Russell R.S., Liang C., Wainberg M.A. Is HIV-1 RNA dimerization a prerequisite for packaging? Yes, no, probably?. Retrovirology 2004, 1(1):23.
134. Sakai H., Shibata R., Sakuragi J., Sakuragi S., Kawamura M., Adachi A. Cell-dependent requirement of human immunodeficiency virus type 1 Vif protein for maturation of virus particles. Journal of Virology 1993, 67(3):1663-1666.
135. Santa-Marta M., Aires da Silva F., Fonseca A., Goncalves J. HIV-1 Vif can directly inhibit APOBEC3G-mediated cytidine deamination by using a single amino acid interaction and without protein degradation. Journal of Biological Chemistry 2005, 280:8765-8775.
136. Schafer A., Bogerd H.P., Cullen B.R. Specific packaging of APOBEC3G into HIV-1 virions is mediated by the nucleocapsid domain of the gag polyprotein precursor. Virology 2004, 328(2):163-168.
137. Schmitt K., Hill M.S., Ruiz A., Culley N., Pinson D.M., Wong S.W., Stephens E.B. Mutations in the highly conserved SLQYLA motif of Vif in a simian-human immunodeficiency virus result in a less pathogenic virus and are associated with G-to-A mutations in the viral genome. Virology 2009, 383(2):362-372.
138. Schrofelbauer B., Senger T., Manning G., Landau N.R. Mutational alteration of human immunodeficiency virus type 1 Vif allows for functional interaction with nonhuman primate APOBEC3G. Journal of Virology 2006, 80(12):5984-5991.
139. Semrad K. Proteins with RNA chaperone activity: a world of diverse proteins with a common task-impediment of RNA misfolding. Biochemistry Research International 2011, 2011:532908.
140. Sheehy A.M., Gaddis N.C., Choi J.D., Malim M.H. Isolation of a human gene that inhibits HIV-1 infection and is suppressed by the viral Vif protein. Nature 2002, 418(6898):646-650.
141. Sheehy A.M., Gaddis N.C., Malim M.H. The antiretroviral enzyme APOBEC3G is degraded by the proteasome in response to HIV-1 Vif. Nature Medicine 2003, 9(11):1404-1407.
142. Shen N., Jette L., Liang C., Wainberg M.A., Laughrea M. Impact of human immunodeficiency virus type 1 RNA dimerization on viral infectivity and of stem-loop B on RNA dimerization and reverse transcription and dissociation of dimerization from packaging. Journal of Virology 2000, 74(12):5729-5735.
143. Shindo K., Takaori-Kondo A., Kobayashi M., Abudu A., Fukunaga K., Uchiyama T. The enzymatic activity of CEM15/Apobec-3G is essential for the regulation of the infectivity of HIV-1 virion but not a sole determinant of its antiviral activity. Journal of Biological Chemistry 2003, 278(45):44412-44416.
144. Simon J.H., Gaddis N.C., Fouchier R.A., Malim M.H. Evidence for a newly discovered cellular anti-HIV-1 phenotype. Nature Medicine 1998, 4(12):1397-1400.
145. Simon J.H., Carpenter E.A., Fouchier R.A., Malim M.H. Vif and the p55(Gag) polyprotein of human immunodeficiency virus type 1 are present in colocalizing membrane-free cytoplasmic complexes. Journal of Virology 1999, 73(4):2667-2674.
146. Simon V., Zennou V., Murray D., Huang Y., Ho D.D., Bieniasz P.D. Natural variation in Vif: differential impact on APOBEC3G/3F and a potential role in HIV-1 diversification. PLoS Pathogens 2005, 1(1):e6.
147. Smith J.L., Bu W., Burdick R.C., Pathak V.K. Multiple ways of targeting APOBEC3-virion infectivity factor interactions for anti-HIV-1 drug development. Trends in Pharmacological Sciences 2009, 30(12):638-646.
148. Sova P., Volsky D.J. Efficiency of viral DNA synthesis during infection of permissive and nonpermissive cells with Vif-negative human immunodeficiency virus type 1. Journal of Virology 1993, 67(10):6322-6326.
149. Stanley B.J., Ehrlich E.S., Short L., Yu Y., Xiao Z., Yu X.F., Xiong Y. Structural insight into the human immunodeficiency virus Vif SOCS box and its role in human E3 ubiquitin ligase assembly. Journal of Virology 2008, 82(17):8656-8663.
150. Stopak K., de Noronha C., Yonemoto W., Greene W.C. HIV-1 Vif blocks the antiviral activity of APOBEC3G by impairing both its translation and intracellular stability. Molecular Cell 2003, 12(3):591-601.
151. Strebel K., Daugherty D., Clouse K., Cohen D., Folks T., Martin M.A. The HIV 'A' (sor) gene product is essential for virus infectivity. Nature 1987, 328(6132):728-730.
152. Suspene R., Rusniok C., Vartanian J.P., Wain-Hobson S. Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Research 2006, 34:4677-4684.
153. Svarovskaia E.S., Xu H., Mbisa J.L., Barr R., Gorelick R.J., Ono A., Freed E.O., Hu W.S., Pathak V.K. Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAs. Journal of Biological Chemistry 2004, 279(34):35822-35828.
154. Syed F., McCrae M.A. Interactions in vivo between the Vif protein of HIV-1 and the precursor (Pr55(GAG)) of the virion nucleocapsid proteins. Archives of Virology 2009, 154(11):1797-1805.
155. Techtmann S.M., Ghirlando R., Kao S., Strebel K., Maynard E.L. Hydrodynamic and functional analysis of HIV-1 Vif oligomerization. Biochemistry 2012, 51(10):2078-2086.
156. Teng B., Burant C.F., Davidson N.O. Molecular cloning of an apolipoprotein B messenger RNA editing protein. Science 1993, 260(5115):1816-1819.
157. Tian C., Yu X., Zhang W., Wang T., Xu R., Yu X.F. Differential requirement for conserved tryptophans in human immunodeficiency virus type 1 Vif for the selective suppression of APOBEC3G and APOBEC3F. Journal of Virology 2006, 80(6):3112-3115.
158. Tisné C. Structural bases of the annealing of primer tRNA(3Lys) to the HIV-1 viral RNA. Current HIV Research 2005, 3(2):147-156.
159. Tisné C., Roques B.P., Dardel F. The annealing mechanism of HIV-1 reverse transcription primer onto the viral genome. Journal of Biological Chemistry 2004, 279(5):3588-3595.
160. Tompa P., Csermely P. The role of structural disorder in the function of RNA and protein chaperones. FASEB Journal 2004, 18(11):1169-1175.
161. Tompa P., Kovacs D. Intrinsically disordered chaperones in plants and animals. Biochemistry and Cell Biology 2010, 88(2):167-174.
162. Tsuchihashi Z., Brown P.O. DNA strand exchange and selective DNA annealing promoted by the human immunodeficiency virus type 1 nucleocapsid protein. Journal of Virology 1994, 68:5863-5870.
163. Tsuchihashi Z., Khosla M., Herschlag D. Protein enhancement of hammerhead ribozyme catalysis. Science 1993, 262:99-102.
164. von Schwedler U., Song J., Aiken C., Trono D. Vif is crucial for human immunodeficiency virus type 1 proviral DNA synthesis in infected cells. Journal of Virology 1993, 67(8):4945-4955.
165. Wichroski M.J., Ichiyama K., Rana T. Analysis of HIV-1 Vif-mediated proteasome-dependent depletion of APOBEC3G: correlating function and subcellular localization. Journal of Biological Chemistry 2005, 280:8387-8396.
166. Wiegand H.L., Doehle B.P., Bogerd H.P., Cullen B.R. A second human antiretroviral factor, APOBEC3F, is suppressed by the HIV-1 and HIV-2 Vif proteins. EMBO Journal 2004, 23(12):2451-2458.
167. Wolfe L.S., Stanley B.J., Liu C., Eliason W.K., Xiong Y. Dissection of the HIV Vif interaction with human E3 ubiquitin ligase. Journal of Virology 2010, 84(14):7135-7139.
168. Wu W., Henderson L.E., Copeland T.D., Gorelick R.J., Bosche W.J., Rein A., Levin J.G. Human immunodeficiency virus type 1 nucleocapsid protein reduces reverse transcription pausing at a secondary structure near the murine leukemia virus polypurine tract. Journal of Virology 1996, 70:7132-7142.
169. Xiao Z., Ehrlich E., Yu Y., Luo K., Wang T., Tian C., Yu X.F. Assembly of HIV-1 Vif-Cul5 E3 ubiquitin ligase through a novel zinc-binding domain-stabilized hydrophobic interface in Vif. Virology 2006, 349(2):290-299.
170. Xiao Z., Ehrlich E., Luo K., Xiong Y., Yu X.F. Zinc chelation inhibits HIV Vif activity and liberates antiviral function of the cytidine deaminase APOBEC3G. FASEB Journal 2007, 21(1):217-222.
171. Xue B., Mizianty M.J., Kurgan L., Uversky V.N. Protein intrinsic disorder as a flexible armor and a weapon of HIV-1. Cellular and Molecular Life Sciences 2011.
172. Yamamoto Y., Saito Y., Iida S., Asano J., Sone S., Adachi A. Functional analysis of Vif genes derived from various primate immunodeficiency viruses. Virus Genes 1997, 14(3):195-200.
173. Yang X., Gabuzda D. Mitogen-activated protein kinase phosphorylates and regulates the HIV-1 Vif protein. Journal of Biological Chemistry 1998, 273(45):29879-29887.
174. Yang X., Goncalves J., Gabuzda D. Phosphorylation of Vif and its role in HIV-1 replication. Journal of Biological Chemistry 1996, 271(17):10121-10129.
175. Yang S., Sun Y., Zhang H. The multimerization of human immunodeficiency virus type I Vif protein: a requirement for Vif function in the viral life cycle. Journal of Biological Chemistry 2001, 276(7):4889-4893.
176. Yang B., Gao L., Li L., Lu Z., Fan X., Patel C.A., Pomerantz R.J., DuBois G.C., Zhang H. Potent suppression of viral infectivity by the peptides that inhibit multimerization of human immunodeficiency virus Type 1 (HIV-1) Vif proteins. Journal of Biological Chemistry 2003, 278(8):6596-6602.
177. Yang Y., Guo F., Cen S., Kleiman L. Inhibition of initiation of reverse transcription in HIV-1 by human APOBEC3F. Virology 2007, 365(1):92-100.
178. Yu X., Yu Y., Liu B., Luo K., Kong W., Mao P., Yu X.F. Induction of APOBEC3G ubiquitination and degradation by an HIV-1 Vif-Cul5-SCF complex. Science 2003, 302(5647):1056-1060.
179. Yu Q., Konig R., Pillai S., Chiles K., Kearney M., Palmer S., Richman D., Coffin J.M., Landau N.R. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nature Structural & Molecular Biology 2004, 11(5):435-442.
180. Yu Y., Xiao Z., Ehrlich E.S., Yu X., Yu X.F. Selective assembly of HIV-1 Vif-Cul5-Elongin B-Elongin C E3 ubiquitin ligase complex through a novel SOCS box and upstream cysteines. Genes and Development 2004, 18(23):2867-2872.
181. Zennou V., Perez-Caballero D., Gottlinger H., Bieniasz P.D. APOBEC3G incorporation into human immunodeficiency virus type 1 particles. Journal of Virology 2004, 78(21):12058-12061.
182. Zhang H., Pomerantz R.J., Dornadula G., Sun Y. Human immunodeficiency virus type 1 Vif protein is an integral component of an mRNP complex of viral RNA and could be involved in the viral RNA folding and packaging process. Journal of Virology 2000, 74(18):8252-8261.
183. Zhang H., Yang B., Pomerantz R.J., Zhang C., Arunachalam S.C., Gao L. The cytidine deaminase CEM15 induces hypermutation in newly synthesized HIV-1 DNA. Nature 2003, 424(6944):94-98.
184. Zhang W., Chen G., Niewiadomska A.M., Xu R., Yu X.F. Distinct determinants in HIV-1 Vif and human APOBEC3 proteins are required for the suppression of diverse host anti-viral proteins. PLoS ONE 2008, 3(12):e3963.
185. Zhang W., Du J., Evans S.L., Yu Y., Yu X.F. T-cell differentiation factor CBF-beta regulates HIV-1 Vif-mediated evasion of host restriction. Nature 2011.
186. Zhen A., Wang T., Zhao K., Xiong Y., Yu X.F. A single amino acid difference in human APOBEC3H variants determines HIV-1 Vif sensitivity. Journal of Virology 2010, 84(4):1902-1911.
187. Zheng Y.H., Irwin D., Kurosu T., Tokunaga K., Sata T., Peterlin B.M. Human APOBEC3F is another host factor that blocks human immunodeficiency virus type 1 replication. Journal of Virology 2004, 78(11):6073-6076.
188. Zou J.X., Luciw P.A. The requirement for Vif of SIVmac is cell-type dependent. Journal of General Virology 1996, 77(Pt 3):427-434.